etrials Chosen by MacuSight as its EDC and IVR Solutions Provider On Three Ophthalmology Studies
16 Aprile 2009 - 3:31PM
Business Wire
etrials Worldwide, Inc. (NASDAQ:ETWC), a leading provider of
adaptive eClinical software and services that optimize clinical
trial management by turning data into intelligence and shortening
the pathway to an actionable study endpoint, announced today that
MacuSight Inc., has selected etrials� Trial Intelligence electronic
data capture (EDC) and etrials� Site Intelligence IVR solutions as
the central component of its clinical data management process,
playing a key role in helping MacuSight to glean actionable
information from its clinical trial data, thereby enhancing and
accelerating decision-making.
"The quality of data and the ability to complete a thorough data
analysis are critical success factors for any clinical study.
etrials� Trial Intelligence EDC solution affords us rapid and
accurate data collection, and offers the ability to integrate
pertinent IVR data into EDC in real-time," said Joel Naor, M.D.,
MacuSight�s Chief Medical Officer. �Every opportunity to
improve data collection efficiencies moves us that much closer to
bringing these important new ophthalmology therapies to
market.�
MacuSight Inc., a privately-held pharmaceutical company based in
Union City, California, focuses on developing innovative
therapeutics for the treatment of severe ocular diseases and
conditions. The company is dedicated to preserving patients' vision
by identifying known, highly-potent and broad-acting small molecule
drug compounds that may possess efficacy in treating and/or
preventing diseases or conditions of the eye.
"In these times of serious economic scrutiny, the pressure on
companies like MacuSight to produce innovative products in a
cost-efficient manner has never been greater,� said M. Denis
Connaghan, CEO and president of etrials. �It�s about working
smarter and our eClinical solutions deliver significant time and
costs savings with greater access to actionable information. We are
proud to be involved in MacuSight�s efforts to develop these novel
treatments.�
After a formal evaluation of several eClinical vendors, the
MacuSight team selected the etrials Trial Intelligence EDC and IVR
solutions for not only their best-of-breed functionality, but also
their nimble and experienced client teams who would be implementing
these systems as an integral component in the MacuSight studies�
data management, enrollment and randomization efforts.
About MacuSight
MacuSight is a privately-held pharmaceutical company focused on
developing innovative therapeutics for the treatment of severe
ocular diseases and conditions. The company is dedicated to
preserving patients' vision by identifying known, highly-potent and
broad-acting small molecule drug compounds that may possess
efficacy in treating and/or preventing diseases or conditions of
the eye. As part of its unique product development philosophy,
MacuSight also concentrates on the optimal delivery of these
compounds into the eye. By combining its compounds with innovative
delivery approaches, the company strives to optimize the efficacy,
safety, convenience and cost-effectiveness of its product
candidates. For more information, visit www.macusight.com.
About etrials(R)
etrials Worldwide, Inc. (Nasdaq: ETWC), a leading provider of
eClinical software and services to pharmaceutical, biotechnology,
medical device and contract research organizations, offers
adaptive, Web-based tools that work together to coordinate data
capture, logistics, patient interaction and trial management �
turning data into intelligence and shortening the pathway to an
actionable study endpoint. etrials is one of the only top-tier
solution providers that offers electronic data capture (EDC),
interactive voice and Web response (IVR/IWR), electronic patient
diaries (eDiary) as part of a flexible and integrated
software-as-a-service (SaaS) platform or as individual solutions to
capture high quality data from multiple pivot points to enable
real-time access for perfectly informed decision-making. As an
experienced leader, etrials has facilitated over 900 trials
involving more than 450,000 patients in 70 countries, and has
participated in 42 studies that resulted in 14 approved new drug
applications and/or regulatory approvals. To learn more visit us at
www.etrials.com. etwcf
Forward-Looking Statements
This announcement may contain forward-looking statements,
including statements regarding the size, number of sites and
patients, new projects, modifications to existing projects, and
duration of clinical trial projects awarded to the Company. These
statements involve risks and uncertainties. Actual results could
differ materially from those discussed. Factors that could cause or
contribute to such differences include, but are not limited to, the
need to finalize definitive agreements for the awards, delays in
the current schedule for clinical trials by the client, utilization
of our software and services by clients to a lesser degree than is
currently expected and early termination of the projects, all of
which are possible because our agreements do not generally have
minimum volume guarantees and can be terminated without penalty by
clients. More information about potential factors which could cause
actual results to differ from the forward-looking statements
included in this announcement is included in our filings with the
Securities and Exchange Commission, including the "Risk Factors"
Section of the Form 10-K filed on March 10, 2009. All
forward-looking statements are based on information available to us
on the date hereof, and we assume no obligation to update such
statements.
etrials� is the registered trademark in the United States of
etrials Worldwide, Inc. Other marks belong to their respective
owners and are used with permission.
Grafico Azioni Etrials Worldwide (MM) (NASDAQ:ETWC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Etrials Worldwide (MM) (NASDAQ:ETWC)
Storico
Da Giu 2023 a Giu 2024